CD Biosynsis provides integrated Yeast Strain Development and Screening Service to rapidly create high-performance microbial cell factories for industrial biotechnology and research applications. Our platform spans the entire strain engineering process, from initial host selection and rational genetic modification to high-throughput validation and optimization. We specialize in developing robust yeast strains (primarily Saccharomyces cerevisiae and Pichia pastoris) with enhanced tolerance, accelerated growth, and significantly improved production titers of target chemicals, proteins, or biofuels. By combining advanced genomic tools with automated screening, we accelerate the discovery and selection of superior strains, saving clients significant time and resources in their bioproduction pipeline.
Get a QuoteDeveloping an industrial yeast strain is a multi-faceted challenge involving engineering for high yield, pathway efficiency, and environmental robustness. Our systematic approach utilizes the Design-Build-Test-Learn (DBTL) cycle to create highly competitive strains. We don't just engineer a single gene; we engineer the entire cellular chassis. The critical bottleneck of strain development is often the 'Test' phase; our services overcome this by employing automated, high-throughput screening (HTS) techniques that can analyze thousands of genetic variants simultaneously, rapidly identifying the best performers and feeding actionable data back into the next design cycle.
Host Strain Chassis Engineering
Creation of optimized base strains by knocking out competing pathways, improving growth rate, and increasing tolerance to stress factors (e.g., ethanol, inhibitors).
Synthetic Pathway Integration
Precise, stable chromosomal integration of complex, multi-gene biosynthetic pathways using multiplex CRISPR tools and advanced DNA assembly techniques.
Regulatory Element Libraries
Construction of targeted promoter/terminator libraries to optimize the expression level of every gene within a pathway for balanced flux.
Automated Screening
Use of robotic platforms and high-density microplates for rapid cultivation and phenotyping of thousands of engineered strains.
Fluorescent Biosensors
Implementation of yeast-compatible biosensors to rapidly and non-destructively measure the intracellular concentration of target metabolites or precursors.
Growth and Titer Profiling
Quantitative analysis of strain growth kinetics and final product titer across varying environmental and nutritional conditions.
Fermentation Condition Testing
Testing top-performing strains in micro-bioreactors or small-scale bioreactors to simulate fed-batch industrial environments (DO, pH, feed strategy).
Strain Stability Assessment
Long-term assessment of genetic and phenotypic stability under continuous culture conditions, critical for large-scale production runs.
Genetic Cleanup
Removal of selection markers and residual genetic elements to comply with regulatory standards for commercial production.
Automated Liquid Handling
High-precision robotic systems for reproducible execution of HTS assays and media preparation across large sample sets.
Fluorescence-Activated Cell Sorting (FACS)
Utilized for ultra-high-throughput sorting of individual cells based on fluorescent biosensor signals, enabling rapid selection of the top 0.1% of performers.
AI/ML Predictive Modeling
Application of Machine Learning to analyze screening data and predict optimal strain configurations, guiding rational design for the next DBTL iteration.
Specialty Chemical Production
Development of yeast strains for high-titer production of specialty chemicals, including food ingredients, flavors, and fragrances.
Biofuel and Bioenergy Strains
Engineering yeast for improved xylose/cellobiose utilization and enhanced tolerance to fermentation inhibitors for cost-effective biofuel production.
Pharmaceutical Precursors
Creation of chassis strains capable of synthesizing complex drug precursors, such as cannabinoids, opioids, or artemisinic acid.
An efficient, data-driven pathway to superior strains.
Design & Assembly
Library Generation
High-Throughput Screening
Validation & Delivery
Design: Define genetic targets and expression levels using computational modeling (AI/ML).
Assembly: Synthesize DNA parts and assemble expression cassettes via standard molecular biology.
Transformation: Introduce genetic variants into the yeast host using high-efficiency methods (electroporation, chemically induced).
Library Creation: Generate a diversified library of thousands of engineered strains.
HTS: Screen the entire library using robotic automation and biosensors to identify top performers based on the target metric (e.g., titer, growth).
FACS/Data Analysis: Isolate top strains and use AI to interpret data for the next design round.
QC: Verify the genome sequence and stability of the best strains (PCR, sequencing).
Validation: Test final strains in micro-bioreactors to confirm performance at scale and deliver the validated strain.
Accelerated DBTL Cycles
HTS and AI integration cut down strain optimization time from years to months, achieving target titers faster.
Ultra-High-Throughput Screening
Capability to screen libraries exceeding 10,000 variants, significantly increasing the probability of finding a superior performer.
Industrial Robustness
Strains are designed and tested for enhanced stability, growth, and stress tolerance under relevant industrial conditions.
Comprehensive Characterization
Detailed reports including genetic confirmation, performance data, and stability testing for seamless transition to scale-up.
"The combination of their advanced CRISPR editing and rapid HTS capabilities allowed us to find a highly productive strain that was previously out of reach using manual screening methods."
Dr. Alan Ross, Head of Fermentation, Industrial Biotechnology
"The strain developed by CD Biosynsis showed exceptional robustness and stability in our pilot bioreactors, confirming their rigorous testing procedures under industrial conditions."
Ms. Elena Santos, Process Development Scientist, Biofuel Company
"Their use of fluorescent biosensors and FACS drastically accelerated our ability to isolate the top 0.5% of producing cells, cutting our strain improvement timeline in half."
Mr. Kenji Tanaka, CTO, Natural Products Synthesis
"We commissioned CD Biosynsis to support an intricate gene editing project with multiple targets. Their talent in producing high-quality work in a short period of time was impressive. Their solutions were custom made to suit our needs, and they went above and beyond to ensure our experiments worked. Their support has been a great asset to our research department and we look forward to further working with them."
Dr. Raj Patel, Principal Investigator, Department of Molecular Biology
"As a pharmaceutical company working to discover new cancer therapies, we require accurate, trustworthy gene editing solutions. CD Biosynsis did more than what we expected when it came to providing strong, accurate CRISPR/Cas9 solutions for our preclinical research. Their technical support team was excellent and responsive, and they quickly replied to our questions. This alliance has been pivotal in helping us move our drug pipeline forward. Thank you, CD Biosynsis, for your amazing service!"
Dr. Clara Rodriguez, Chief Scientist
What is the maximum size of the strain library you can screen?
We routinely handle and screen libraries containing tens of thousands of unique yeast variants using our automated HTS and robotic platforms.
How do you ensure the genetic stability of the final engineered strain?
We prioritize stable chromosomal integration over plasmid-based expression. Final strains undergo long-term cultivation and re-sequencing verification to confirm genetic stability under relevant industrial pressures.
Can you develop strains resistant to high concentrations of target products?
Yes. We use advanced adaptive laboratory evolution (ALE) combined with rational engineering to enhance product tolerance, which is critical for achieving high final titers.
What type of information do you require to start a project?
We need information about the target product, the required yield/titer goal, the preferred host organism (if known), and any existing genetic sequences or pathways you wish to incorporate.
How much does Metabolic Engineering services cost?
The cost of Metabolic Engineering services depends on the project scope, complexity of the target compound, the host organism chosen, and the required yield optimization. We provide customized quotes after a detailed discussion of your specific research objectives.
Do your engineered strains meet regulatory standards?
We adhere to high quality control standards in all strain construction and optimization processes. While we do not handle final regulatory approval, our detailed documentation and compliance with best laboratory practices ensure your engineered strains are prepared for necessary regulatory filings (e.g., GRAS, FDA).
What to look for when selecting the best gene editing service?
We provide various gene editing services such as CRISPR-sgRNA library generation, stable transformation cell line generation, gene knockout cell line generation, and gene point mutation cell line generation. Users are free to select the type of service that suits their research.
Does gene editing allow customisability?
Yes, we offer very customised gene editing solutions such as AAV vector capsid directed evolution, mRNA vector gene delivery, library creation, promoter evolution and screening, etc.
What is the process for keeping data private and confidential?
We adhere to the data privacy policy completely, and all customer data and experimental data are kept confidential.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.